David H. Alpers MDEmeritus William B. Kountz Professor of Medicine, Washington University School of Medicine, St Louis, Missouri
Dr David Alpers is a graduate of Harvard College and Harvard Medical School, and received his initial medical training at the Massachusetts General Hospital (MGH), a Harvard teaching hospital. After training in molecular biology at NIH, he returned to the GI Division at the MGH before leaving to become Chief of the Division of Gastroenterology at Washington University School of Medicine (WUMS), a post he held for 28 years. His laboratory research has focused on enterocyte physiology and nutrient absorption (especially vitamin B12). Clinical research involved studies on the nosology of irritable bowel syndrome and its relationship to psychiatric illness. He has served as editor-in-chief for the American Journal of Physiology/GI Liver Physiology and Current Opinion in Gastroenterology (Small Intestine/Nutrition), and as Associate editor for the Journal of Clinical Investigation and American Journal of Clinical Nutrition (2008-2017), and on the Editorial Board of the J Biological Chemistry, Gastroenterology, and many other journals. He is the author of 230 peer-reviewed scientific/clinical papers, was the senior author of the Manual of Nutritional Therapeutics (6th edition 2015), and an Associate Editor of Yamada’s Textbook of Gastroenterology through its first 5 editions.
DisclosuresDr. Alpers has served on many Scientific Advisory Committees, including for the MGH (chairman), the Bill and Melinda Gates Foundation (zinc absorption in third world countries), and most recently for the Alimentary Pharmabiotic Centre, U Cork, Ireland, and the Sackler Center for Biomedicine and Nutrition Research at Rockefeller U. He has been involved for decades as a consultant in drug development on assets related to gastroenterology, nutrition, and drug safety, most recently with GlaxoSmithKline (Hepatic Safety Panel), Takeda North America (Global Safety Board), and Otsuka North America (Hepatic Safety Panel).
Recent Contributions to PracticeUpdate:
- Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care
- No Negative Birth Outcomes in Offspring of Men Treated With AZA/6-MP
- Early Environmental Risk Factors for Irritable Bowel Syndrome and Dyspepsia
- Antidepressants for Functional Esophageal Disorders